Torsemide

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

托拉塞米；Torasemide

白色或类白色粉末

DMSO ：1 mg/mL (2.87 mM)

Cl- channel

Torsemide inhibits aldosterone secretion by adrenal cells from rats, cows, and guinea pigs stimulated in vitro by potassium, angiotensin, dibutyryl cyclic AMP, ACTH, or corticosterone. Torsemide's primary site of action is the thick ascending loop of Henle in the nephron, where it promotes excretion of sodium, water, and chloride via interaction with the Na+, K+, 2Cl− cotransporter. Torsemide interferes with the secretion of, and receptor ligand binding of, the mineralocorticoid aldosterone in a dose-dependent manner.

Torsemide results in elevated levels of circulating angiotensin II and aldosterone (supportive of interference with aldosterone at the receptor level) in dogs with experimental mitral regurgitation whereas furosemide results in elevated levels of angiotensin II, only. Torsemide increases the BUN and plasma creatinine concentrations in rats, compared with the baseline value. Torsemide immediately increases urine volume significantly.